| 引用本文: | 彭晋伟,周保柱,廖国斌,汪涛.CYP2C19基因多态性对艾司奥美拉唑治疗胃食管反流病疗效的影响[J].中国现代应用药学,2020,37(18):2254-2257. |
| PENG Jinwei,ZHOU Baozhu,LIAO Guobin,WANG Tao.Effects of CYP2C19 Gene Polymorphism on the Efficacy of Esmeralazole in the Treatment of Gastroesophageal Reflux Disease[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(18):2254-2257. |
|
| 摘要: |
| 目的 研究CYP2C19基因多态性对艾司奥美拉唑治疗胃食管反流病疗效的影响。方法 选择2019年1月—2019年8月就诊于中国人民解放军联勤保障部队第九〇一医院消化内科胃食管反流病92例患者作为研究对象。采用DNA微阵列芯片法对患者进行基因分型，其中32例为强代谢型（extensive metabolizer，EM），36例为中等代谢型（intermediate metabolizer，IM），24例为弱代谢型（poor metabolizer，PM）。应用注射用艾司奥美拉唑钠40 mg qd治疗2周方案，分别于第7天、第14天测定24 h胃内pH值和消化内镜检查临床疗效。结果 在艾司奥美拉唑治疗第7天、第14天时，EM、IM、PM代谢型患者pH>4总时间百分比有显著性差异（P<0.05）；在艾司奥美拉唑治疗第14天，EM、IM、PM代谢型患者临床疗效有显著性差异（P<0.05）。结论 艾司奥美拉唑治疗胃食管反流病的抑酸作用和疗效与CYP2C19基因多态性密切相关。 |
| 关键词: 艾司奥美拉唑 胃食管反流病 CYP2C19基因多态性 临床疗效 胃内pH值 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.18.016 |
| 分类号:R969.4 |
| 基金项目: |
|
| Effects of CYP2C19 Gene Polymorphism on the Efficacy of Esmeralazole in the Treatment of Gastroesophageal Reflux Disease |
|
PENG Jinwei1, ZHOU Baozhu1, LIAO Guobin2, WANG Tao1
|
|
1.The 901 st Hospital of the PLA Joint Logistics Support Force, Department of Pharmacy, Hefei 230031, China;2.The 901 st Hospital of the PLA Joint Logistics Support Force, Department of Gastroenterology, Hefei 230031, China
|
| Abstract: |
| OBJECTIVE To explore the effects of CYP2C19 gene polymorphism on the efficacy of esmeralazole in the treatment of gastroesophageal reflux disease. METHODS A total of 92 patients with gastroesophageal reflux disease admitted to the department of gastroenterology of The 901st Hospital of the PLA Joint Logistics Support Force from January 2019 to August 2019 were selected. DNA microarray method was applied to perform genetic typing in the patients, and the patients were divided into three groups according to the genotype:32 patients of extensive metabolizer(EM), 36 patients of intermediate metabolizer(IM), and 24 patients of poor metabolizer(PM). Using the 2-week regimen of esomeprazole 40 mg qd, 24-hour gastric pH and curative effects were respectively measured by digestive endoscopy on 7th and 14th day. RESULTS On the 7th day and 14th day after the treatment of esomeprazole, the total time percentages of pH> 4 in EM, IM and PM metabolic patients were significantly different(P<0.05). On the 14th day after the treatment of esomeprazole, there was a significant difference in the clinical efficacy of EM, IM and PM metabolic patients(P<0.05). CONCLUSION The acid inhibition and clinical efficacy of esomeprazole in the treatment of gastroesophageal reflux disease are closely related to CYP2C19 gene polymorphism. |
| Key words: esomeprazole gastroesophageal reflux disease CYP2C19 genepolymorphism clinical efficacy gastric pH value |
